Milestone Group Inc. Buys Shares of 2,532 Eli Lilly and Company (NYSE:LLY)

Milestone Group Inc. acquired a new stake in Eli Lilly and Company (NYSE:LLY) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 2,532 shares of the company’s stock, valued at approximately $213,000.

Other hedge funds have also recently made changes to their positions in the company. Assetmark Inc. raised its stake in shares of Eli Lilly and by 226.1% in the first quarter. Assetmark Inc. now owns 12,913 shares of the company’s stock valued at $1,086,000 after buying an additional 8,953 shares in the last quarter. HL Financial Services LLC raised its stake in shares of Eli Lilly and by 15.8% in the first quarter. HL Financial Services LLC now owns 93,272 shares of the company’s stock valued at $7,845,000 after buying an additional 12,735 shares in the last quarter. Quantitative Investment Management LLC bought a new stake in shares of Eli Lilly and during the first quarter valued at approximately $5,601,000. Twin Capital Management Inc. raised its stake in shares of Eli Lilly and by 297.7% in the first quarter. Twin Capital Management Inc. now owns 44,380 shares of the company’s stock valued at $3,733,000 after buying an additional 33,220 shares in the last quarter. Finally, Norinchukin Bank The increased its position in shares of Eli Lilly and by 5.0% in the first quarter. Norinchukin Bank The now owns 115,527 shares of the company’s stock valued at $9,717,000 after buying an additional 5,480 shares during the last quarter. 75.61% of the stock is currently owned by institutional investors.

Shares of Eli Lilly and Company (NYSE LLY) traded down 0.12% during trading on Tuesday, hitting $81.97. The stock had a trading volume of 3,292,993 shares. Eli Lilly and Company has a 52 week low of $64.18 and a 52 week high of $86.72. The company has a market capitalization of $86.48 billion, a price-to-earnings ratio of 35.47 and a beta of 0.34. The company’s 50 day moving average price is $83.03 and its 200 day moving average price is $81.54.

Eli Lilly and (NYSE:LLY) last posted its quarterly earnings results on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, topping analysts’ consensus estimates of $1.05 by $0.06. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The company had revenue of $5.82 billion for the quarter, compared to analysts’ expectations of $5.60 billion. During the same quarter in the previous year, the firm posted $0.86 EPS. Eli Lilly and’s revenue was up 7.8% on a year-over-year basis. Analysts predict that Eli Lilly and Company will post $4.16 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Shareholders of record on Tuesday, August 15th will be issued a dividend of $0.52 per share. The ex-dividend date of this dividend is Friday, August 11th. This represents a $2.08 dividend on an annualized basis and a yield of 2.54%. Eli Lilly and’s payout ratio is 90.04%.

ILLEGAL ACTIVITY WARNING: “Milestone Group Inc. Buys Shares of 2,532 Eli Lilly and Company (NYSE:LLY)” was reported by BBNS and is owned by of BBNS. If you are viewing this report on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this report can be accessed at https://baseballnewssource.com/markets/milestone-group-inc-takes-position-in-eli-lilly-and-company-nyselly-updated-updated-updated/1195158.html.

Several equities analysts have issued reports on the company. Berenberg Bank reiterated a “buy” rating and issued a $98.00 price objective on shares of Eli Lilly and in a research report on Friday. BMO Capital Markets restated a “sell” rating and set a $73.00 target price on shares of Eli Lilly and in a research report on Friday. TheStreet upgraded Eli Lilly and from a “c+” rating to a “b+” rating in a research report on Tuesday, July 25th. UBS AG downgraded Eli Lilly and to a “hold” rating and set a $85.00 target price for the company. in a research report on Wednesday, July 26th. Finally, Oppenheimer Holdings, Inc. downgraded Eli Lilly and from an “outperform” rating to a “market perform” rating and set a $90.00 target price for the company. in a research report on Wednesday, July 26th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $88.27.

In other news, VP Michael J. Harrington sold 22,833 shares of the company’s stock in a transaction on Friday, June 9th. The shares were sold at an average price of $79.97, for a total value of $1,825,955.01. Following the transaction, the vice president now owns 62,056 shares of the company’s stock, valued at $4,962,618.32. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, major shareholder Lilly Endowment Inc sold 220,000 shares of the company’s stock in a transaction on Monday, July 31st. The stock was sold at an average price of $83.09, for a total transaction of $18,279,800.00. Following the completion of the transaction, the insider now directly owns 124,049,283 shares in the company, valued at approximately $10,307,254,924.47. The disclosure for this sale can be found here. Insiders have sold a total of 669,733 shares of company stock worth $55,845,287 in the last three months. Insiders own 0.20% of the company’s stock.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with our FREE daily email newsletter.

 


Latest News

Despite Changes to Reduce The Length of Games, MLB Games are Actually Getting Longer
Despite Changes to Reduce The Length of Games, MLB Games are Actually Getting Longer
Despite Hitting Home Run, Judge Sets Longest Game Streak for Strikeouts
Despite Hitting Home Run, Judge Sets Longest Game Streak for Strikeouts
Los Angeles Dodgers Move 50 Games Over .500
Los Angeles Dodgers Move 50 Games Over .500
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Bryce Harper Latest Star to Suffer Injury
Bryce Harper Latest Star to Suffer Injury
Chicago Cubs Must Survive Without Willson Contreras
Chicago Cubs Must Survive Without Willson Contreras


Leave a Reply

 
© 2006-2017 BBNS.